More recently, targeted therapies directed at NSCLC harboring anaplastic lymphoma kinase (ALK) fusions and ROS1 fusions have produced similar results in terms of overall response rate (ORR) and progression-free survival (PFS) [5,6]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.